Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

Highlights • Clinical utility of the VeriStrat serum protein test was assessed in LUX-Lung 8. • Patients were classified as VeriStrat ‘Good’ (VS-G) or VeriStrat ‘Poor’ (VS-P). • VS-G classification is associated with favorable survival outcomes versus VS-P. • In VS-G patients, survival outcomes are...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-07, Vol.109, p.101-108
Hauptverfasser:	Gadgeel, Shirish, Goss, Glenwood, Soria, Jean-Charles, Felip, Enriqueta, Georgoulias, Vassilis, Lu, Shun, Cobo, Manuel, Syrigos, Konstantinos, Lee, Ki Hyeong, Göker, Erdem, Guclu, Salih Z, Isla, Dolores, Morabito, Alessandro, Dupuis, Nicholas, Bühnemann, Claudia, Krämer, Nicole, Solca, Flavio, Ehrnrooth, Eva, Ardizzoni, Andrea
Format:	Artikel
Sprache:	eng
Schlagworte:	Afatinib Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarker Biomarkers, Tumor - metabolism Blood Proteins - metabolism Carcinoma, Squamous Cell - diagnosis Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Erlotinib Erlotinib Hydrochloride - therapeutic use Female Hematologic Tests Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - mortality LUX-lung 8 Male Middle Aged Predictive Value of Tests Pulmonary/Respiratory Quinazolines - therapeutic use Retrospective Studies Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Squamous cell carcinoma of the lung Survival Analysis Treatment Outcome VeriStrat
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Clinical utility of the VeriStrat serum protein test was assessed in LUX-Lung 8. • Patients were classified as VeriStrat ‘Good’ (VS-G) or VeriStrat ‘Poor’ (VS-P). • VS-G classification is associated with favorable survival outcomes versus VS-P. • In VS-G patients, survival outcomes are superior with afatinib versus erlotinib.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2017.05.010